title: A multifunctional biphasic suspension of mesoporous silica encapsulated with YVO4:Eu3+ and Fe3O4 nanoparticles: synergistic effect towards cancer therapy and imaging.
abstract: Polyol mediated synthesized luminescent YVO(4):Eu(3+) nanoparticles (NPs) have been encapsulated in mesoporous silica nanoparticles (MSNs)  using the sol-gel process. X-ray diffraction and Fourier transform infrared spectroscopy along with transmission electron microscopy confirm the encapsulation of the YVO(4):Eu(3+) NPs in the SiO(2) matrix. N(2) adsorption/desorption analysis confirms the mesoporous nature of the MSNs and YVO(4):Eu(3+)-MSNs. No significant quenching of the YVO(4):Eu(3+) luminescence is observed for YVO(4):Eu(3+)-MSNs. This nanocomposite has been tested as a potential drug carrier. Efficient loading of doxorubicin hydrochloride (DOX), a typical anticancer drug, is observed which reaches up to 93% in 8 mg ml(-1) of YVO(4):Eu(3+)-MSNs. pH sensitive release of DOX is observed, with 54% release for pH 4.3 and 31% in a physiological environment (pH 7.4). Both MSNs and YVO(4):Eu(3+)-MSNs nanocomposites do not show accountable toxicity to two cell lines, i.e. HeLa and MCF-7. However, as desired, toxicity is observed when cells are incubated with DOX loaded YVO(4):Eu(3+)-MSNs. Laser scanning confocal microscopy images confirm the uptake of the nanocomposite in both cell lines. The morphology of the cells (MCF-7) changes after incubation with DOX loaded YVO(4):Eu(3+)-MSNs, indicating an interaction of DOX with the cells. More cytotoxicity to both cell lines with ∼90% killing is observed due to the synergistic effect of magnetic fluid hyperthermia and chemotherapy using a biphasic suspension of superparamagnetic iron oxide magnetic nanoparticles and DOX loaded YVO(4):Eu(3+)-MSNs. In addition, an AC magnetic field triggers an enhanced drug release.
authors: Department of Metallurgical Engineering and Materials Science, Indian Institute of Technology Bombay, Mumbai-400076, India.
authors: N
authors: N
authors: Shanta Singh
authors: Hrishikesh
authors: H
authors: Kulkarni
authors: Lina
authors: L
authors: Pradhan
authors: D
authors: D
authors: Bahadur
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D005063:Europium / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D052203:Ferrosoferric Oxide / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D008280:Magnetics / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D012822:Silicon Dioxide / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D014638:Vanadates / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D015019:Yttrium / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D014638:Vanadates; D005063:Europium; D015019:Yttrium; D012822:Silicon Dioxide; D004317:Doxorubicin; D052203:Ferrosoferric Oxide